Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 189,228 shares at $53.14 ($9.9M) on 2024-12-03, disclosed to the SEC on 2024-12-04.
Scheduled sale ($9.9M) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $52.17 | 1,960 | $102K | 1.0% |
| 2 | $52.17 | 1,960 | $102K | 1.0% |
| 3 | $52.26 | 83,640 | $4.4M | 44.1% |
| 4 | $52.26 | 83,640 | $4.4M | 44.1% |
| 5 | $53.04 | 600 | $32K | 0.3% |
| 6 | $53.13 | 1,900 |
| $101K |
| 1.0% |
| 7 | $53.14 | 6,315 | $336K | 3.4% |
| 8 | $53.14 | 6,315 | $336K | 3.4% |
| 9 | $54.05 | 1,405 | $76K | 0.8% |
| 10 | $54.05 | 1,405 | $76K | 0.8% |
| 11 | $54.14 | 88 | $5K | 0.0% |
| Total | $52.36 avg | 189,228 | $9.9M | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |